Management of carcinoid syndrome: a systematic review and meta-analysis.

Abstract:

:Carcinoid syndrome (CS) is a debilitating disease caused by functional neuroendocrine tumors. Several treatment options are available to alleviate the hormonal symptoms, but their relative efficacy is unknown. Online databases were searched for publications on the treatment of CS symptoms. Independent reviewers assessed relevant publications for study quality and outcome. Meta-analysis of the outcomes of the intervention on CS-related symptoms was stratified by the type of treatment. We found 3682 therapeutic interventions on CS-specific outcomes were collected from 93 studies. Overall, the study qualities were poor with only six randomized controlled clinical trials. The somatostatin analogs octreotide and lanreotide induced symptomatic improvement in 65-72% and biochemical response in 45-46% of patients. An increase in dose or frequency or interclass switch led to a reduction of flushes and/or diarrhea in 72-84% of cases. Retrospective, institutional series showed that liver-directed therapy can improve symptoms in 82% of CS patients with a liver-dominant disease. The serotonin synthesis inhibitor telotristat ethyl reduced bowel movements in 40% of patients with diarrhea refractory to somatostatin analogs. Interferon-alpha controlled CS symptoms in 45-63% of cases. Favorable response has been noted after radionuclide therapy in subgroup analyses of studies not specifically involving CS patients. Chemotherapy and everolimus did not induce a significant response in the CS. We conclude that several treatment lines can be offered to patients suffering from the carcinoid syndrome. Initiation of randomized controlled trials with a primary outcome on carcinoid syndrome symptoms is strongly recommended.

journal_name

Endocr Relat Cancer

journal_title

Endocrine-related cancer

authors

Hofland J,Herrera-Martínez AD,Zandee WT,de Herder WW

doi

10.1530/ERC-18-0495

subject

Has Abstract

pub_date

2019-03-01 00:00:00

pages

R145-R156

issue

3

eissn

1351-0088

issn

1479-6821

pii

ERC-18-0495.R1

journal_volume

26

pub_type

杂志文章,meta分析
  • Current mouse and cell models in prostate cancer research.

    abstract::Mouse models of prostate cancer (PCa) are critical for understanding the biology of PCa initiation, progression, and treatment modalities. Here, we summarize recent advances in PCa mouse models that led to new insights into specific gene functions in PCa. For example, the study of transgenic mice with TMPRSS2/ERG, an ...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1530/ERC-12-0285

    authors: Wu X,Gong S,Roy-Burman P,Lee P,Culig Z

    更新日期:2013-06-24 00:00:00

  • Comprehensive screening for PD-L1 expression in thyroid cancer.

    abstract::PD-L1 expression is being considered a potential biomarker for response of anti-PD-1 or anti-PD-L1 agents in various tumors. The reported frequency of PD-L1 positivity varies in thyroid carcinomas, and multiple factors may contribute to the variability in PD-L1 positivity. We evaluated the PD-L1 expression in various ...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-16-0421

    authors: Ahn S,Kim TH,Kim SW,Ki CS,Jang HW,Kim JS,Kim JH,Choe JH,Shin JH,Hahn SY,Oh YL,Chung JH

    更新日期:2017-02-01 00:00:00

  • Endothelins and hypoxia-inducible factor in cancer.

    abstract::The endothelin system is a family of three similar small peptides, two G-protein-coupled receptors and two proteinases. Endothelins have several physiological roles, notably in embryonic differentiation and vascular homeostasis. Numerous types of tumour express endothelins and their regulation is often aberrant when c...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1677/ERC-07-0057

    authors: Grimshaw MJ

    更新日期:2007-06-01 00:00:00

  • The risk of metachronous cancers in patients with small-intestinal carcinoid tumors: a US population-based study.

    abstract::Small-intestinal carcinoids (SIC) are the most common small-bowel malignancies. We sought to determine the risk of developing SIC before and after other primary malignancies (PM) and the prognosis of patients with SIC, with and without another PM. We used the Surveillance, Epidemiology, and End Results database to ide...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-11-0392

    authors: Amin S,Warner RR,Itzkowitz SH,Kim MK

    更新日期:2012-05-24 00:00:00

  • MAPK- and AKT-activated thyroid cancers are sensitive to group I PAK inhibition.

    abstract::The number of individuals who succumb to thyroid cancer has been increasing and those who are refractory to standard care have limited therapeutic options, highlighting the importance of developing new treatments for patients with aggressive forms of the disease. Mutational activation of MAPK signaling, through BRAF a...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-19-0188

    authors: Knippler CM,Saji M,Rajan N,Porter K,La Perle KMD,Ringel MD

    更新日期:2019-08-01 00:00:00

  • Role of exon-16-deleted HER2 in breast carcinomas.

    abstract::A splice variant of the human gene HER2, lacking exon-16 (DeltaHER2) which encodes a small extracellular region, has been described. This altered receptor forms disulfide bond-stabilized homodimers. We report here that the DeltaHER2 splice variant represents about 9% of the HER2 mRNA obtained from most of the 46 breas...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1677/erc.1.01047

    authors: Castiglioni F,Tagliabue E,Campiglio M,Pupa SM,Balsari A,Ménard S

    更新日期:2006-03-01 00:00:00

  • GnRH antagonists in the treatment of gynecological and breast cancers.

    abstract::Approximately 80% of human ovarian and endometrial cancers and 50% of breast cancers express GnRH and its receptor as part of an autocrine regulatory system. After binding of its ligand the tumor GnRH receptor couples to G-protein alphai and activates a variety of intracellular signaling mechanisms. (1) Through activa...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1677/erc.0.0100291

    authors: Emons G,Gründker C,Günthert AR,Westphalen S,Kavanagh J,Verschraegen C

    更新日期:2003-06-01 00:00:00

  • Human heterochromatin protein 1 isoform HP1beta enhances androgen receptor activity and is implicated in prostate cancer growth.

    abstract::There are currently few successful therapies for castration-resistant prostate cancer (CRPC). CRPC is thought to result from augmented activation of the androgen/androgen receptor (AR) signaling pathway, which could be enhanced by AR cofactors. In this study, heterochromatin protein 1beta (HP1beta), but not HP1alpha o...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1677/ERC-09-0321

    authors: Shiota M,Song Y,Yokomizo A,Tada Y,Kuroiwa K,Eto M,Oda Y,Inokuchi J,Uchiumi T,Fujimoto N,Seki N,Naito S

    更新日期:2010-05-18 00:00:00

  • Differential sensitivities to lactate transport inhibitors of breast cancer cell lines.

    abstract::The tumour microenvironment is known to be acidic due to high glycolytic rates of tumour cells. Monocarboxylate transporters (MCTs) play a role in extracellular acidification, which is widely known to be involved in tumour progression. Recently, we have described the upregulation of MCT1 in breast carcinomas and its a...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-13-0132

    authors: Morais-Santos F,Miranda-Gonçalves V,Pinheiro S,Vieira AF,Paredes J,Schmitt FC,Baltazar F,Pinheiro C

    更新日期:2013-12-16 00:00:00

  • Estrogen promotes tumor progression in a genetically defined mouse model of lung adenocarcinoma.

    abstract::Numerous epidemiological observations point to sex differences in lung cancer etiology and progression. The present study was aimed at understanding the bases of these sex differences. To test the effect of estradiol on tumor progression, we used a mouse model based on conditional Kras expression and concurrent deleti...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1677/ERC-08-0002

    authors: Hammoud Z,Tan B,Badve S,Bigsby RM

    更新日期:2008-06-01 00:00:00

  • The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R.

    abstract::Imatinib mesylate (IM), a small molecule that is a selective inhibitor of the ABL, platelet derived growth factor receptor (PDGFR-R) and stem cell ligand receptor (c-kit) tyrosine kinases (TK). IM was also found to inhibit the TK activity of BCR/ABL fusion protein produced in chronic myelogenous leukemia, with marked ...

    journal_title:Endocrine-related cancer

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1677/erc.1.01124

    authors: Gross DJ,Munter G,Bitan M,Siegal T,Gabizon A,Weitzen R,Merimsky O,Ackerstein A,Salmon A,Sella A,Slavin S,Israel Glivec in Solid Tumors Study Group.

    更新日期:2006-06-01 00:00:00

  • Targeted therapy for adrenocortical tumors in transgenic mice through their LH receptor by Hecate-human chorionic gonadotropin beta conjugate.

    abstract::Novel strategies are needed for the treatment of adrenocortical tumors that are usually resistant to chemotherapy. Hecate, a 23-amino acid lytic peptide, was conjugated to the 15-amino acid (81-95) fragment of the human chorionic gonadotropin beta (CGbeta) chain, which would selectively kill cancer cells expressing th...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1677/ERC-08-0015

    authors: Vuorenoja S,Rivero-Müller A,Ziecik AJ,Huhtaniemi I,Toppari J,Rahman NA

    更新日期:2008-06-01 00:00:00

  • FSH inhibits ovarian cancer cell apoptosis by up-regulating survivin and down-regulating PDCD6 and DR5.

    abstract::Ovarian epithelial cancer is the leading cause of death among gynecological malignancies. FSH may increase the risk of ovarian malignancy and play an important role in ovarian carcinogenesis. Our previous studies showed that FSH increases the expression of VEGF through survivin. In this study, the function and mechani...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1677/ERC-09-0308

    authors: Huang Y,Jin H,Liu Y,Zhou J,Ding J,Cheng KW,Yu Y,Feng Y

    更新日期:2010-11-30 00:00:00

  • Quality of life and psychometric functionality in patients with differentiated thyroid carcinoma.

    abstract::We studied the psychological performance and the quality of life in patients with differentiated thyroid carcinoma, either during treatment with chronic suppressive doses of levothyroxine, or during the withdrawal of levothyroxine needed to perform whole-body scanning with radioactive iodine, with those of appropriate...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1677/erc.0.0100601

    authors: Botella-Carretero JI,Galán JM,Caballero C,Sancho J,Escobar-Morreale HF

    更新日期:2003-12-01 00:00:00

  • Tetrac as an anti-angiogenic agent in cancer.

    abstract::The thyroid hormones T3 and T4 have emerged as pro-angiogenic hormones with important implications for cancer management. Endogenous circulating hormone levels may help stimulate cancer progression and limit the effectiveness of anticancer therapy, though clinical data remain inconclusive. The capacity of thyroid horm...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1530/ERC-19-0058

    authors: Schmohl KA,Nelson PJ,Spitzweg C

    更新日期:2019-06-01 00:00:00

  • Role of chromosomal instability in cancer progression.

    abstract::Cancer cells often display chromosomal instability (CIN), a defect that involves loss or rearrangement of the cell's genetic material - chromosomes - during cell division. This process results in the generation of aneuploidy, a deviation from the haploid number of chromosomes, and structural alterations of chromosomes...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1530/ERC-17-0187

    authors: McClelland SE

    更新日期:2017-09-01 00:00:00

  • Loss of neuronatin expression is associated with promoter hypermethylation in pituitary adenoma.

    abstract::The imprinted gene, neuronatin (NNAT), is one of the most abundant transcripts in the pituitary and is thought to be involved in the development and maturation of this gland. In a recent whole-genome approach, exploiting a pituitary tumour cell line, we identified hypermethylation associated loss of NNAT. In this repo...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1677/ERC-09-0008

    authors: Revill K,Dudley KJ,Clayton RN,McNicol AM,Farrell WE

    更新日期:2009-06-01 00:00:00

  • Leptin deficiency suppresses MMTV-Wnt-1 mammary tumor growth in obese mice and abrogates tumor initiating cell survival.

    abstract::Obesity increases both the risk and mortality associated with many types of cancer including that of the breast. In mice, obesity increases both incidence of spontaneous tumors and burden of transplanted tumors. Our findings identify leptin, an adipose secreted cytokine, in promoting increased mammary tumor burden in ...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-11-0102

    authors: Zheng Q,Dunlap SM,Zhu J,Downs-Kelly E,Rich J,Hursting SD,Berger NA,Reizes O

    更新日期:2011-07-11 00:00:00

  • Intratumoral concentration of sex steroids and expression of sex steroid-producing enzymes in ductal carcinoma in situ of human breast.

    abstract::It is well known that sex steroids play important roles in the development of invasive ductal carcinoma (IDC) of the human breast. However, biological significance of sex steroids remains largely unclear in ductal carcinoma in situ (DCIS), regarded as a precursor lesion of IDC, which is partly due to the fact that the...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1677/ERC-07-0092

    authors: Shibuya R,Suzuki T,Miki Y,Yoshida K,Moriya T,Ono K,Akahira J,Ishida T,Hirakawa H,Evans DB,Sasano H

    更新日期:2008-03-01 00:00:00

  • Genetics and clinical characteristics of hereditary pheochromocytomas and paragangliomas.

    abstract::Pheochromocytomas (PCCs) and paragangliomas (PGLs) are rare neuroendocrine tumors of the adrenal glands and the sympathetic and parasympathetic paraganglia. They can occur sporadically or as a part of different hereditary tumor syndromes. About 30% of PCCs and PGLs are currently believed to be caused by germline mutat...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1530/ERC-11-0170

    authors: Welander J,Söderkvist P,Gimm O

    更新日期:2011-12-01 00:00:00

  • Obesity and cancer: mechanistic insights from transdisciplinary studies.

    abstract::Obesity is associated with a range of health outcomes that are of clinical and public health significance, including cancer. Herein, we summarize epidemiologic and preclinical evidence for an association between obesity and increased risk of breast and prostate cancer incidence and mortality. Moreover, we describe dat...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1530/ERC-15-0400

    authors: Allott EH,Hursting SD

    更新日期:2015-12-01 00:00:00

  • Siglec-6 is expressed in gestational trophoblastic disease and affects proliferation, apoptosis and invasion.

    abstract::Sialic acid immunoglobulin-like lectin (Siglec)-6 is a transmembrane receptor that binds leptin. Leptin is an obesity-associated peptide hormone overexpressed in gestational trophoblastic disease (GTD). GTD encompasses several placental abnormalities that range from benign to malignant. Among GTD, molar placentas are ...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-11-0379

    authors: Rumer KK,Post MD,Larivee RS,Zink M,Uyenishi J,Kramer A,Teoh D,Bogart K,Winn VD

    更新日期:2012-11-19 00:00:00

  • Low phosphorylation of estrogen receptor alpha (ERalpha) serine 118 and high phosphorylation of ERalpha serine 167 improve survival in ER-positive breast cancer.

    abstract::Endocrine therapy has become the most important treatment option for women with estrogen receptor (ER)-positive breast cancer. Urgently needed are prognostic assays that can identify those who need additional adjuvant therapy, such as signal transduction inhibitors or chemotherapy, for ER-positive early breast cancer....

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1677/ERC-08-0078

    authors: Yamashita H,Nishio M,Toyama T,Sugiura H,Kondo N,Kobayashi S,Fujii Y,Iwase H

    更新日期:2008-09-01 00:00:00

  • Uptake and antiproliferative effect of molecular iodine in the MCF-7 breast cancer cell line.

    abstract::This study analyzes the uptake and antiproliferative effect of two different chemical forms of iodine, iodide (I-) and molecular iodine (I2), in MCF-7 cells, which are inducible for the Na+/I- symporter (NIS) and positive for pendrin (PDS). The mouse fibroblast cell line NIH3T3 was used as control. Our results show th...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1677/erc.1.01250

    authors: Arroyo-Helguera O,Anguiano B,Delgado G,Aceves C

    更新日期:2006-12-01 00:00:00

  • Chromogranin A as a marker of neuroendocrine neoplasia: an Italian Multicenter Study.

    abstract::Elevated circulating chromogranin A (CgA) levels are found in neuroendocrine tumors (NETs), but the diagnostic usefulness of this marker is still debatable. To assess the role of CgA for the diagnosis of gastroenteropancreatic (GEP) NETs and the identification of metastatic patients, an Italian multicenter observation...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,多中心研究

    doi:10.1677/ERC-07-0001

    authors: Zatelli MC,Torta M,Leon A,Ambrosio MR,Gion M,Tomassetti P,De Braud F,Delle Fave G,Dogliotti L,degli Uberti EC,Italian CromaNet Working Group.

    更新日期:2007-06-01 00:00:00

  • Thyrotoxicosis with concomitant thyroid cancer.

    abstract::Thyrotoxicosis with concomitant thyroid cancer is rare and poorly recognized, which may result in delayed diagnosis, inappropriate treatment and even poor prognosis. To provide a comprehensive guidance for clinicians, the etiology, pathogenesis, diagnosis and treatment of this challenging setting were systematically r...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-19-0129

    authors: Fu H,Cheng L,Jin Y,Chen L

    更新日期:2019-07-01 00:00:00

  • 177Lu-octreotate therapy for neuroendocrine tumours is enhanced by Hsp90 inhibition.

    abstract::177Lu-octreotate is an FDA-approved radionuclide therapy for patients with gastroenteropancreatic neuroendocrine tumours (NETs) expressing somatostatin receptors. The 177Lu-octreotate therapy has shown promising results in clinical trials by prolonging progression-free survival, but complete responses are still uncomm...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-18-0509

    authors: Hofving T,Sandblom V,Arvidsson Y,Shubbar E,Altiparmak G,Swanpalmer J,Almobarak B,Elf AK,Johanson V,Elias E,Kristiansson E,Forssell-Aronsson E,Nilsson O

    更新日期:2019-04-01 00:00:00

  • miR-205 targets angiogenesis and EMT concurrently in anaplastic thyroid carcinoma.

    abstract::The current study aims to evaluate for the first time the inhibitory roles of miR-205 in the pathogenesis of anaplastic thyroid carcinoma. In addition, we investigated the mechanisms by which miR-205 regulates angiogenesis and epithelial-to-mesenchymal transition (EMT) in cancer. Two anaplastic thyroid carcinoma cell ...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-17-0497

    authors: Vosgha H,Ariana A,Smith RA,Lam AK

    更新日期:2018-03-01 00:00:00

  • Progress in breast cancer chemoprevention.

    abstract::Over the past years there have been significant advances in breast cancer treatment and early detection. For the first time, a decrease in cancer mortality has been observed. Recently, much progress has been made in the understanding of carcinogenesis partly due to available new technologies to detect early molecular ...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1677/erc.0.0090015

    authors: Arun B,Hortobagyi GN

    更新日期:2002-03-01 00:00:00

  • HES5 silencing is an early and recurrent change in prostate tumourigenesis.

    abstract::Prostate cancer is the most common cancer in men, resulting in over 10 000 deaths/year in the UK. Sequencing and copy number analysis of primary tumours has revealed heterogeneity within tumours and an absence of recurrent founder mutations, consistent with non-genetic disease initiating events. Using methylation prof...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-14-0454

    authors: Massie CE,Spiteri I,Ross-Adams H,Luxton H,Kay J,Whitaker HC,Dunning MJ,Lamb AD,Ramos-Montoya A,Brewer DS,Cooper CS,Eeles R,UK Prostate ICGC Group.,Warren AY,Tavaré S,Neal DE,Lynch AG

    更新日期:2015-04-01 00:00:00